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ABSTRACT
Background: Early stage small cell lung cancer (T1-2N0M0SCLC) represents 7% of all SCLC. 
The standard treatment in patients with intrathoracic SCLC disease is the use of concurrent 
chemoradiotherapy (CRT). Nowadays, the recommended management of this highly selected group is 
surgical resection due to favorable survival outcomes. For medically inoperable patients or those who 
refuse surgery, there is an increasing interest in evaluating the role of Stereotactic Body Radiotherapy 
(SBRT) for T1-2N0SCLC, transferring the favorable experience obtained on inoperable NSCLC 
(Non-Small-cell Lung Cancer). In the era of multimodality treatment, adjuvant systemic therapy plays 
an important role even in the management of early SCLC, increasing the disease-free survival (DFS) 
and Overall Survival (OS). The benefit of Prophylactic Cranial Irradiation (PCI), that currently has a 
Category I recommendation for localized stage SLCL, remains controversial in this selected subgroup 
of patients due to the lower risk of brain metastasis.
Aim: This review summarizes the most relevant data on the local management of T1-2N0M0SCLC 
(surgery and radiotherapy), and evaluates the relevance of adjuvant treatment.
Relevance for patients: Provides a critical evaluation of best current clinical management options 
for T1-2N0M0 SCLC.
1. Introduction
Small cell lung cancer (SCLC) accounts for 15-20% of all lung cancers [1-3]. It is strongly 
associated with cigarette smoking and the most aggressive subtype with a median overall 
survival time of 7 months and 5-year relative survival rates of 5-7% [4,5]. SCLC is most 
often diagnosed at advanced stages. Using the Veterans Administration Lung Cancer Study 
Group stage system, roughly 60% of the patients present with limited-stage disease while 
40% present with extensive stage [1]. Early-stage SCLC (T1-2N0SCLC), defined as Stages 
I and II according to the American Joint Committee on Cancer Staging [6,7], comprises 7% 
of all SCLC and 0.29% of all lung cancers [8].
Even for this selected subgroup of patients, the 5-year overall survival (OS) remains 
poor, <35%, despite an intensive treatment. At this moment, the international guidelines 
recommend a local therapy as the first option for early SCLC. Surgical resection for fit 
patients has shown favorable survival outcomes in several studies [9,10], whereas definitive 
radiotherapy (RT) treatment is recommended for inoperable patients in addition to systemic 
therapy. Recently, the development of a highly conformal RT treatment, Stereotactic Body 
Radiotherapy (SBRT) with excellent results in early NSCLC, has led to an increased interest 
in its use in early well-staged SCLC patients [11,12].
The authors present a literature review of the current role of surgery and SBRT in early 
stage small cell lung cancer to provide a critical evaluation of the available data from existing 
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studies. A comprehensive search was conducted in the NHS 
evidence (www.evidence.nhs.uk), PubMed (www.ncbi.nlm.nih.
gov/pmc/) and Embase (www.embase.com), from 1966 to 2019. 
Studies published in languages other than English were excluded. 
Search terms included: Early small cell lung cancer, Small cell 
lung cancer, Stereotactic body radiotherapy, Stereotactic ablative 
radiotherapy, and Surgery. Prospective, retrospective, meta-
analysis, case–control, and case reports with more than 5 patients 
were included in the study.
2. Treatment of ES-SCLC. Surgery versus SBRT
2.1. Defining limited/early stage SCLC
In 1957, the Veterans Administration Lung Cancer Study 
Group (VALSG) established a dichotomous stage system for 
SCLC: Limited disease when the tumor was confined to one 
hemithorax and extended disease in case of bilateral pulmonary 
or extrathoracic involvement. From a practical point of view, a 
limited disease would be encompassed within an acceptable RT 
field, while the RT field required for treating the extended disease 
would be too large and would be associated with inadmissible 
toxicity. This simplified two-stage system, applied in clinical 
practice and trials during many years, has proven to be adequate 
for most clinical decisions and carries additional prognostic 
information [13]. In 1989, the IASLC proposed a modification 
to the VALSG classification of the limited disease including 
contralateral mediastinal or supraclavicular lymph node metastases 
and ipsilateral pleural effusions independent of cytology.
In 1993, Shepherd et al. points out the relevance of an accurate 
clinical staging of limited SCLC as a helpful system to differentiate 
prognostic subgroups and proposed the term of “very limited 
disease” for the SCLC with a negative cervical mediastinoscopy 
and/or no evidence of enlarged mediastinal lymph nodes on 
radiologic examinations [14].
The prognostic value of the TNM staging system has been 
observed in small series of patients undergoing surgical resection 
for SCLC, mainly in the setting of a multimodal therapy [14-22]. 
Nonetheless, the TNM staging system for SCLC was not formally 
recommended by the AJCC till 2009. In 2009 (7th edition) and 
2015 (8th edition), based on the prognostic value of both clinical 
and pathological TNM staging, the International Union for Cancer 
Control (UICC) Classification of Malignant Tumors recommended 
the use of the TNM staging system for SCLC [23,24]. A recent study 
conducted by Abdel-Rahman validates both the prognostic value of 
TNM lung cancer staging system and the improvement over the 
prognostic value of the old veterans’ administration system [25].
Despite the above-mentioned, a considerable variation exists 
concerning which definition should be used for classifying SCLC, 
even in the context of multidisciplinary team meetings.
2.2. Surgery for ES-SCLC
2.2.1. Surgery alone for ES-SCLC
Concurrent CRT is considered to be the standard of care for 
patients with ES-SCLC, resulting in a median survival of 17 months 
and an overall 5-year survival of 10% [1,26]. Historically, surgery 
alone has been considered to have a limited role in the primary 
treatment of early-stage SCLC as it had been associated with an 
overall 5-year survival close to 0%. In 1969, the British Medical 
Research Council Trial randomly allocated 144 operable patients 
with a SCLC diagnosed on bronchial biopsy to either surgical 
resection or RT. The mean and 10-year overall survival results 
showed that radical RT was associated to a moderately better 
result than surgery (300 days for radical RT vs. 199 days for 
surgery – P=0.04 – and 1% for radical RT vs. 0% for surgery). 
The conclusion of this study was that radical RT is preferable to 
surgery in the treatment of patients with SCLC [27-29]. These 
results were broadly in line with those published by Mountain 
et al. in 1974 [30] and Martini et al. in 1975 [31].
2.2.2. Surgery within multimodality treatment for T1-2N0M0 
SCLC
2.2.2.1. Rationale for surgery in early stage SCLC
Systemic therapy plus concurrent RT is considered the gold 
standard for patients with T1-2N0SCLC and RT is a crucial 
component for the local treatment. However, the local in-field 
failure rate after CRT is high and ranges from 30 to 70% [17,32-35]. 
In addition, despite having achieved complete radiologic response, 
up to 70% of these patients will have detectable residual disease in 
the resected specimen [32,36].
The above-mentioned highlights a possible role of surgery in 
the local treatment of T1-2N0SCLC. Many authors have addressed 
this matter [37-40]. The rationale for surgical resection in SCLC 
can be summarized as follows:
1. Intraoperative diagnosis on frozen section of SCLC of a 
solitary nodule not suspected to be a SCLC. Although this 
scenario is very unlikely due to the aggressiveness of the 
SCLC, there is a small subgroup of patients (3-5%) who 
presents initially with disease strictly limited to the lung [8]. 
In this subset of patients, aggressive treatment (anatomic 
resection, systematic lymphadenectomy, and adjuvant CT or 
CRT) can achieve similar survival rates to that of non–small-
cell lung cancer.
 SCLC tend to be accurately diagnosed intraoperatively 
on frozen section, in some cases it can represent a difficult 
diagnostic problem [41]. In a series of 125 unexpected 
SCLC diagnosed after pulmonary resection, only 78 
cases were diagnosed as SCLC by intraoperative frozen 
section examinations. The other 47 cases were diagnosed 
intraoperatively as poorly differentiated, non-specific lung 
cancer or carcinoid tumors. There was also inconsistencies 
between the clinical and pathological stage of these unexpected 
SCLC mainly caused by nodal upstaging, highlighting the 
importance of an adequate systematic nodal dissection [42].
2. Surgical resection for very limited-SCLC (defined as 
T1N0, T2N0) may improve local control compared to 
CRT [8-10,16,18,21,34,43-88]. The first sites of recurrence 
after complete remission are either the primary tumor 
region or the hilar and mediastinal lymph nodes. It has 
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been demonstrated that local control after multimodality 
treatment including complete surgical resection is 95-
100% [15,16,18,48,74,89,90].
 Accurate hilar and mediastinal staging are mandatory in this 
subgroup of patients with a potentially resectable SCLC. 
Ideally, the mediastinal staging should include invasive 
techniques as endobronchial ultrasonographic needle 
aspiration, endoscopic ultrasonographic needle aspiration, 
conventional and extended cervical mediastinoscopy, 
anterior mediastinotomy, and video-assisted thoracic surgery. 
Thomas et al. studied 477 patients with clinical Stage I SCLC 
(cT1-2aN0M0) from the National Cancer Database treated 
with curative-intent resection, followed by adjuvant therapy. 
Initial clinical and final pathological stages were compared to 
determine the upstaging rate; it was 25%, 30% due to a higher 
pathologic T descriptor, and 81% due to the presence of nodal 
disease. Overall 5-year survival was significantly worse for 
upstaged patients compared with those who remained a 
pathologically Stage I (36% vs. 52%, P<0.001) [60].
3. Combined histology tumors (a SCLC tumor with a NSCLC 
component). The incidence of combined SCLC ranges from 
2% to 28% [91-95]. It is thought that relapse or failure to 
respond to CT may be due to the NSCLC component.
4. Salvage surgery for chemoresistant localized SCLC or local 
relapse after an initial response to C/CRT. In this scenario, 
selected patients may benefit from surgical resection more 
than a second-line CT [17,96,97].
2.2.2.2. Does surgical resection of T1-2N0SCLC improve overall 
survival?
The role of surgery in small cell lung cancer (SCLC) is 
controversial. Two old randomized controlled trials have shown 
no significant benefit from surgery compared to conventional 
treatment [36,98]. In the largest study conducted by Lad et al., 
a total of 146 patients with SCLC received induction CT. 
Patients achieving at least partial response after induction and 
fit enough for thoracotomy were randomized to surgery or no 
intervention. Complete resection rate was 77%. All patients 
had chest and brain irradiation postoperatively. There was no 
difference in survival between the two groups. The conclusion 
of the authors was that surgery does not add any benefit in 
terms of survival or local disease control to multimodality 
treatment of SCLC. Nevertheless, quality of the evidence from 
these randomized trials is very low [99] and the results should 
be taken with caution as the staging pre-operative methods; 
pre-operative neoadjuvant therapy and surgical procedures 
used in these studies do not reflect current knowledge and 
clinical practice.
Ever since, many small series (largely retrospective, but also 
Phase II trials, meta-analysis, systematic reviews, and propensity 
matched score analysis) have shown excellent survival for patients 
with T1-2N0SCLC treated surgically, mainly in the setting of a 
multimodal approach [8-10,16,18,21,34,43-88].
Table 1 summarizes surgical and survival data for patients with 
SCLC published in the past 25 years.
Ahmed et al. identified 1902 patients with Stage I SCLC from 
the SEER database. Of these, 28.5% underwent surgical resection, 
a percentage that remained unchanged from 2007 to 2013 despite 
improved outcomes with surgical resection as part of a multimodal 
approach. The authors point out the significant disparities in the 
management of patients with Stage I SCLC and the need to educate 
physicians on the importance to consider surgical resection for 
this subgroup of patients [46].
Jones et al. conducted a best evidence topic published in 2013 
concluding that surgery would be indicated in clinical Stages I 
or II SCLC after an accurate pre-operative staging of mediastinal 
lymph nodes including a mediastinoscopy. In this scenario, surgery 
for T1-2N0SCLC improves the prognosis as part of a multimodal 
treatment. However, patients with Stage III disease are unlikely to 
benefit from surgery [100,101].
The effectiveness of surgery in patients with locally advanced 
SCLC (Stages II and III) has been specifically addressed in 
both retrospective series of cases [10,18,48,74,87,89,100,102] 
and propensity score matching analyses [103]. Data from these 
studies show that surgery is highly effective in local control and is 
associated with a significant overall survival benefit after complete 
resection in the context of a multimodal treatment including 
neoadjuvant/adjuvant chemoradiation and prophylactic cranial 
irradiation (PCI). Nevertheless, the favorable survival associated 
to the surgery-based multi-modality treatment appears to be stage-
dependent, ranging from 20 to 57% (5-year overall probability of 
survival), with a detrimental impact on hazard ratio for OS over 
the stages.
With the aim of assessing the potential role of surgery for 
pathologically confirmed SCLC, Staged T1-4 N0-2 M0 (AJCC 
8th edition), Wei et al. used propensity score-matching analysis 
to compare overall survival (OS) in a matched cohort of 1562 
patients from the SEER database (2004-2014). In the matched 
cohort, surgery was associated with a significant 5-year OS 
improvement (from 16.8% to 36.7%, P<0.001). After adjustment 
for confounders using a Cox regression model, survival benefit of 
surgery was significant in all subgroups, including N1-2 disease, 
except for patients with a tumor size > 5.0 cm or T3 disease. The 
authors concluded that selected patients (T size <5 cm/T1-2) with 
SCLC would benefit from surgery, including N1-2 disease [104].
Du et al. conducted another propensity score matching analysis 
of patients with SCLC from the SEER database (2010-2015) to 
investigate the impact of surgery on survival. A total of 1,707 
patients were included in the matched cohort. The authors found 
that patients who did not receive surgery had an increased risk of 
death when compared with patients who did. The results support 
that patients with SCLC with Stage I-IIA (T1-2N0M0) and 
selected IIB (N1) may benefit from surgery [105]. Similar results 
were found by Peng et al. in regard to the impact of surgery on 
lung cancer specific survival in a cohort of 2453 patients with early 
stage SCLC from the SEER database [106]. Yu et al. analyzed a 
series of 1560 patients with stage I SCLC from the SEER database, 
of which 399 treated surgically (242 underwent lobectomy, 121 
had local tumor excision/ablation, ten had a pneumonectomy, and 
unknown type of surgery in 21). Most of the surgical group of 
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Number patients Neoadjuvant/adjuvant 
treatments






S 387, RT 1032 
S+RT 154
No S nor RT 556
- 5-year OS T1N0 46.0% versus 
23.8% S versus RT
5-year OS T2N0: 42.6% versus 
24.7% S versus RT
T3N0 or T1-2N1 (stage IIB) SCLC 
patients who underwent S did not 
have higher 5-year OS and LCSS 





Stage I SCLC N=1902
S 427, S+RT 115














match S versus NST
3A
cI-III N=2619 No adjuvant treatment 
24%
NC or NR 4%
AC 27%; AR 1%
ACR 32%; NC or NR 
and AC or AR 2%
Other 10%
_ MST Stage I 38.6 versus 22.9 mos. 
S versus NST
MST Stage II 23.4 versus 20.7 mos. 
S versus NST
MST stage IIIA21.7 versus 16.0 




















N=28 (23 SCLC 
before S)
S 21cI,5 cII,7 
cIII2
NC 8
AC 19, ACR 2






pI-III N=34 NC 3
AC 1, AR 19, 10 CRT








N=349 (68 pIA, 
91 pIB)





pI-III N=122 CT and CRT (not 
specified)






cI-IIIA N=23 AC all - MST 24 mos.
Tsuchiya, 
2005 [83]
Prospective Phase II 
trial 1991-1996
2B
cI-IIIA N=62 AC 42 (69%) - MST not reached in pI stage
MST 449 days in pII stage
MST 712 days in pIIIA disease.
3-year OS 61%
3-year Sv rate cI, cII, cIIIA stage 








N=82 (24 Stage 
I→S + AC)






cI-III SCLC N=69 S 37, NC 32,
AC 41, ACR 7
- 5-year Sv 48.9% cI 33.3% cII 









both, S and 
non-S groups
N=134 S 67 (all AC)
Non-S 67 (all CT)
34% only 
S group
MST 22 mos. (S)
MST 11 mos. (non-S)
5-year OS S 27%, non-S 4%
Table 1. Surgical and survival dates for patients with SCLC (period time revised 1995-2020)
(Contd...)
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patients did not receive radiation therapy. The authors found that 
surgery, even without RT, seems to offer acceptable OS outcomes 
for Stage I patients who undergo lobectomy (5-year OS 50.3%, 
95% CI 43.1-57.1%, for the group of lobectomies without RT and 
57.1%, 95% CI 37.4-72.7%, for the group of lobectomies with 
RT) [65].
Wakeam et al. performed a propensity score matching analysis 
of patients with SCLC from the National Cancer Database. A 
total of 2089 patients with a SCLC clinically Staged I-IIIA were 
matched. The study aimed to evaluate outcomes of curative surgery 
in comparison to CT-based non-surgical treatment. Surgery was 
associated with longer survival across all the stages. In a sub-
analyses by T and N descriptors, significant differences in OS was 
observed in favor of patients who underwent surgical resection 
ofT3/T4 N0 tumors (median OS 33.0 vs. 16.8 months, P=0.008), 
N1 (24.4 vs. 18.3 months P=0.03), and N2 tumors (20.1 vs. 14.6 




Number patients Neoadjuvant/adjuvant 
treatments










NC all If CR to 
NC
MST N0+1 25 mos.
MST N2 14 mos.
MST resected 18 mos.






cI-III SCLC N=60 AC 88%
pII AR (11%)
pIII AR (21%)









N=91 (32 cIA, 30 
cIB)
All 78% 5.5% MST 53 mos. 5-year OS 49% (cIA)











II trial. Institutional 
1991-1995
2B
cIB-cIIIB N=46 IB/IIA had NC+S
IIB/IIIA had NCR+S
- MST all patients 36 mos.
MST R0 patients 68 mos.
5-year Sv rate all patients 46%






cI -III SCLC N=104 51 cI-II received 
S+ACR
53 cIII received 
NC+S + AR
35% MST 28 mos.
5-year OS rate 32%










92 S+AC+AR if 
N1-2 (34 patients)
15 NC
10% MST 18 mos.






cI-IIIA SCLC N=22 NC all – MST 62 mos.
3-year OS rate67%
3-y OS ratecI-II 73%






cI -III SCLC N=46 NC+AC 37.0% AC 
50.5% the S 12,5%
_ 5-year Sv rate cI-II who received 
NC 80.0%
5-year Sv rate cI-II who received 
AC 37.7%
5-year Sv rate cIII-IIIb who 
received NC 10.0%










N=183 AC 100% 2.5-year Sv rate 63% for 68 patients 
after R0-pTN0M0
2.5-year Sv rate 37% for 27 patients 
after R0-pTN2M0
SCLC: Small cell lung cancer; PCI: Prophylactic cranial irradiation; RS: Retrospective study; SEER: Surveillance, epidemiology, and end results database; ISC-LCSG: The Lung Cancer 
Study Group of the International Society of Chemotherapy; S: Surgery; CT: Chemotherapy; RT: Radiotherapy; NCDB, National Cancer Data Base; cIA, clinical stage IA; cIB, clinical stage IB 
IASLC: International Association for the study of Lung Cancer; pI (A): Pathologic stage IA; pI (B), pathologic stage I (B); pII: pathologic stage II; pIII (A): Pathologic stage IIIA; 
pIII (B): pathologic stage IIIB; R0: Complete resection; AC: adjuvant chemotherapy; MST, median survival time; NC: neoadjuvant chemotherapy; ACR: adjuvant chemoradiotherapy. 
CR: complete response; NST: non-surgical treatment; A dash represents lack of information or details; LOE, Level of evidence (From the Centre for Evidence-Based Medicine, http://www.cebm.net.)
Table 1. (Continued)
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months, P=0.007). The authors conclude that surgical resection is 
associated with significantly longer survival for early SCLC [53].
Regarding the type of resection, there is evidence suggesting 
that patients who underwent a lobectomy had significant better 
OS over sublobar resection [8,53,65,67,86,87,90,102,105]. In 
the retrospective study of SCLC patients in the National Cancer 
Data Base published by Combs et al., lobectomy was associated 
with a 5-year overall survival of 40% compared with 21% 
for sublobar and 22% for pneumonectomy (HR for death after 
sublobar resections vs. lobectomy 1.38,95% CI 1.12-1.71) [102]. 
Similar results were found in the propensity-matched analysis 
of survival of patients from the same database published by 
Wakeam et al. [53] comparing resection of Stage I-IIIA SCLC 
with CT-based non-surgical treatment, as well as in the systematic 
review and meta-analysis of the role of surgery in Stage I to III 
SCLC published by Liu et al. [66] and in the study of Schreiber 
et al. [87] using the SEER database to analyze survival outcomes 
of patients who underwent surgery with both localized disease and 
regional SCLC. Du et al. conducted a propensity score matching 
analysis of patients with SCLC included in the SEER database 
from 2010 to 2015 and concluded as well that patients who 
received a sublobar resection had a significant increased risk of 
mortality when compared with patients who received a lobectomy 
(P=0.03) [105].
2.2.2.3. What do guidelines say on surgical treatment of 
T1-2N0SCLC?
There is not a complete agreement on the indication of surgery 
in T1-2N0 SCLC between the different guidelines. The National 
Comprehensive Cancer Network (NCCN) [107], ASTRO [108], 
and ASCO [109] guidelines recommend surgery as the initial 
treatment option in operable patients having a Stage T1-2N0M0 
(I-IIA) SCLC. The ESMO Clinical Practice Guidelines (108) 
recommend surgical treatment for patients with a SCLC stage 
T1-2N0-1M0. All the guidelines state that indication of surgical 
treatment and RT should be based on the American Joint 
Committee on Cancer/Union for International Cancer Control 
TNM Staging System.
An accurate pre-operative mediastinal staging is universally 
recommended before indicating surgical treatment. Nevertheless, 
recommendations to rule out mediastinal lymph node involvement 
differ substantially between guidelines. After a standard 
staging, the NCCN recommends an endoscopic (endobronchial 
and/or endoscopic ultrasound biopsy) or surgical staging 
(mediastinoscopy, mediastinotomy, and videothoracoscopy) of 
the lymph nodes to all patients candidates for definitive surgical 
resection [107]. The ESMO guidelines, however, recommend a 
direct surgical approach in patients without mediastinal lymph 
node involvement on CT scan and PET-CT scan (in these patients, 
mediastinal lymph node biopsy would not be required before 
surgery) and to perform an EBUS and/or mediastinoscopy only 
if there are enlarged or positive lymph nodes on CT scan and/or 
PET-CT scan [110].
With regard to the type of resection, lobectomy with mediastinal 
lymph node dissection is the recommended type of resection.
2.3. SBRT for early ES-SCLC
The standard treatment for patients with intrathoracic 
SCLC disease is concurrent CRT, while surgical resection is 
recommended for patients with early stage SCLC (T1-2N0). 
For medically inoperable patients or those who refuse surgery, 
definitive radiation therapy concurrently with systemic therapy is 
the standard approach. There is an increasing interest in evaluating 
the role of SBRT for inoperable early stage SCLC.
SBRT, otherwise known as stereotactic ablative radiotherapy 
(SABR), is an advanced technique that delivers a highly 
conformed ablative radiation dose with great precision into a 
small tumor volume, usually <5 cm. It is given over a limited 
number of fractions, typically from 3 to 8. This technique allows 
minimizing the dose to surrounding normal tissues due to a 
very steep dose gradient, being the reason for the low toxicity 
(Figure 1).
SBRT has been demonstrated to be an effective treatment for 
medically inoperable early-stage NSCLC, with local control 
rates of 80-90% [111-115]. On the basis of these findings 
and knowing the high radiosensitivity of SCLC, SBRT has 
recently emerged as a potential therapeutic option in medically 
inoperable T1-2N0 SCLC. Principles of SBRT for early 
SCLC, in the absence of other data, are similar to those used 
for early NSCLC: Small volume (<5 cm), non-involvement of 
mediastinal structures, and DBE (dose biological equivalent) 
>100 Gy. Despite not having randomized studies, the use of this 
technique is increasing, while awaiting new results that validate 
this treatment approach.
2.3.1. Review of literature’s data
Table 2 summarizes several retrospective SBRT series for 
patients with early stage SCLC published in recent years: Multi-
institutional retrospective series, database reviews, and cases 
series reports.
Videtic et al. published in 2013 the first results of patients 
with ES-SCLC (T1-T2aN0) treated with SBRT with a dose of 
Figure 1. SBRT planning treatment.
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30 to 60 Gy in 1 to 3 fractions in a small series of six patients. 
Four of them underwent CT and adjuvant prophylactic cranial 
irradiation (PCI). Local control (LC), OS and DFS obtained at 
1 year were 100%, 63% and 75%, respectively. There were no 
regional relapses and no toxicity ≥ G3. Despite a short follow-
up, the author concludes that SBRT in early stage SCLC offers 
excellent local control with low toxicity, being these results 
similar to those obtained in early non-surgical stages of NSCLC 
treated with SBRT [116].
The Japan Radiation Oncology Study Group (JROSG) reported 
in 2015 an abstract with the results of 64 patients with Stage I 
SCLC treated with SBRT, with a dose range of 35-60 Gy in 3 to 19 
fractions. At 2 years, the LC, OS, and Progression-free survival 
(PFS) were 89.3%, 76.3%, and 49.3%, respectively. Eighteen 
patients had regional relapse and 26 had distant metastases. 
Female gender and the use of CT were significantly correlated 
with favorable survival outcome in univariate and multivariate 
analysis [117]. Later, the same group (JROSG) published the 
results of a multi-institutional retrospective series of 43 patients 
with Stage I SCLC treated with SBRT [118]. All patients had 
brain MRI/CT-scan and in 12 of them a staging 18-FDGPET-CT 
was performed. The administered dose was 30-60Gy (3-10 
fractions). Eight patients received CT and PCI was performed 
in other eight. The 2-year OS, PFS, DmPFS (Distant metastatic 
Progression Free Survival), and LC were 72.3%, 44.6%, 47.2%, 
and 80.2%, respectively. In the univariate analysis, female sex 
and Stage IA were favorable prognostic factors for OS and 
PFS. Regional and distant metastases were 28% and 47%. This 
low OS percentage corresponds to a tumor with a propensity 
for early development of metastatic disease, but probably also 
related to insufficient staging and a low proportion of patients 
treated with CT.
In 2017, Verma et al. published a multi-institutional analysis 
of 74 patients treated with SBRT for inoperable Stage I SCLC 
with a median dose of 50 Gy in5 fractions, demonstrating high 
local control (96% at 3 years with low toxicity, 1% Grade >3). 
Table 2. SBRT data for early stage SCLC
Study Study type Inclusion 
criteria








N=6 60 Gy (3 fx)
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SCLC: Small cell lung cancer; CT: Chemotherapy; PCI: Prophylactic cranial irradiation; SBRT: Stereotactic radiation therapy; CFRT: Conventionally fractionated radiation therapy; fx: Fractions; 
OS: Overall survival; LC: Local control; DFS: Disease free survival; Dm1 PFS: Distant metastases free survival; m: Months; y: Years; RS: Retrospective study; NCDB: National Cancer Data 
Base; JRSSBRTSG: Japanese Radiological Society MultiInstitutional SBRT Study Group: RSSPS: RSSearch Patient Registry; LOE: Level of evidence (From the Centre for EvidenceBased 
Medicine: http://www.cebm.net.)
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On multivariate analysis, the addition of CT was associated 
with improved OS and DFS. PCI was not associated with 
survival improvement. The relapses were most commonly 
distant (45.8%) and nodal (25%). After the publication of 
these results, clinical practice guidelines incorporated SBRT 
into the therapeutic strategy of Stage I SCLC for inoperable 
patients [119].
The National Cancer Database (NCDB) has published several 
analyses of patients with early-stage SCLC treated with radiation 
therapy: SBRT or Conventional Fraction Radiation Therapy 
(CFRT) with or without CT. The first of them, published the 
results of 285 patients with Stage T1-T2 SCLC treated with 
SBRT between 2000 and 2013 [120], most of them (83%) in the 
past 5 years. The most common dose received was 48-60 Gy in 
3-5 fractions. Almost half of the patients received CT, being as 
neoadjuvant in 42.7% of them. Younger age and diagnosis in the 
initial years of the study were the only significant predictors of 
CT administration. After a 45.6 months follow-up, 3 and 5 years 
OS were 35.2% and 21.5%. OS was not affected by the time that 
CT was administered: Neoadjuvant or adjuvant. No data about the 
impact of systemic therapy in OS was analyzed in this study. In 
this large group of patients, we can observe the increasing use of 
SBRT technique despite the lack of randomized evidence.
In 2019, the NCDB analyzed 2107 T1-T2N0M0 SCLC, 
all of them treated with CT and RT (SBRT or CFRT). CFRT 
represented 92.9% and the majority was followed by CT (85%). 
On multivariate analyses SBRT technique was not related with 
an improvement of OS (31.2 m vs. 29.2 m, P=0.95). Predicting 
factors of poorer OS were advanced age, male gender, and 
treatment in earlier years [11].
The NCDB recently published, the results for a group of 1378 
patients T1-T2N0M0 SCLC treated with radiation therapy (SBRT 
or CFRT). SBRT group received significantly less CT than CFRT 
group, 35% compared to 88%. SBRT was significantly associated 
with improved survival when CT was given (P<0.001).On 
multivariate analysis in the CT group, adjusting for sex, age, and 
tumor size, the use of SBRT trended to improve survival (P=0.06). 
SBRT was strongly associated with a survival benefit in elderly 
patients [121].
Singh, in 2019 identified 21 patients in the RSSearch Patient 
Registry (RSSPR) with medically inoperable Stage I SCLC 
treated with SBRT. Only four patients received CT. The 1 and 
3-year local control rates were both 100%. 1 and 2-year OS 
were 73.1% and 36.6%, respectively. The study concluded that 
patient with T1N0 had better OS than T2N0, 85.7% and 33.3%, 
respectively. Adjuvant CT improved OS, also for Stage I SCLC 
over SBRT alone [122].
2.3.2. Conclusions about SBRT
In light of the results obtained in these limited series (small 
number of patients, heterogeneous treatments, and low level 
of evidence), we can conclude that: As expected, SBRT offers 
excellent local control, more than 85%, and low toxicity, <5% 
Grade ≥ 3, for inoperable SCLC Stage I, with similar results 
when compared to NSCLC series treated with SBRT. However, 
OS rates are worse than those obtained in NSCLC. According 
to the analyzed series, the OS were 63-83%, 35-76%, and 
21-26% at 1, 3, and 5 years, respectively, due to the high 
tendency of early spreading of SCLC; it can also be secondary 
to insufficient mediastinal and distant staging in many of the 
analyzed series, which often leads to understaging and therefore 
to worse results. Hence, it seems highly recommendable to 
systematically perform a correct regional and distant staging 
with an18-FDG PET-CT-scan and mediastinoscopy or EBUS for all 
patients to correctly assess the impact of SBRT on the survival 
of early-stage SCLC.
2.3.2.1. Adjuvant CT
Another determining factor is the use of CT. The fact that up to 
50% of recurrences are distant must be considered. In the series 
in which CT is analyzed, a significant increase in survival can be 
observed in the subgroup that receives CT, regardless of when it 
is given, and especially for tumors >2 cm [117,119,121]. The use 
of CT and its sequence (neoadjuvant/adjuvant) is heterogeneous 
in the analyzed series; since SBRT only requires few sessions it 
would not delay the beginning of CT, whereas CT would interfere 
with volume delimitation of SBRT. It is, therefore, preferred to 
perform SBRT before CT.
Tumor size at this very early stage of SCLC seems to be an 
important factor in all the analyzed series, as in some of them it 
is observed that tumors >2 cm have worse prognosis than smaller 
ones [119,121,122]. This should be taken into account when 
assessing the need for systemic therapy.
2.3.2.2. RT technique
Regarding the RT technique used, in the series in which 
CFRT is compared to SBRT there is a non-significant trend of 
a better OS in patients treated with SBRT, especially in elderly 
patients [11,121]. Principles of SBRT for SCLC are similar to 
those for NSCLC. The dose of SBRT that is used for SCLC is 
similar to that for NSCLC with a BED >100 Gy. There are no 
studies that have evaluated a different dose. Even though the 
series include only a low number of patients, they have reported 
a low toxicity (<5% G≥3) which represents a clear advantage 
over conventional RT, as almost all patients are elderly and have 
cardiorespiratory comorbidities.
2.3.2.3. PCI
Up to 50% of patients with SCLC will develop brain 
metastasis. Auperin’s meta-analysis [123] showed that PCI 
increases the rate of DFS and reduces the cumulative risk of brain 
metastasis by up to 25%. PCI has a Category I recommendation 
for localized stage SLCL. It cannot be ignored its potential 
neurotoxicity, therefore different approaches to reduce it has 
been utilized, such as the hippocampus’s protection [124,125] or 
the use Memantine [126].
The use of PCI in Stage I SCLC subgroup is controversial 
since the data that we have in retrospective surgical series show 
a lower risk of brain metastasis; it is estimated that between 10 
and 15% will develop them [62,127,128]. Thus, expected benefit 
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in survival could be lower. An approach that seems reasonable in 
the era of advanced imaging in this favorable group of patients 
is active brain MRI surveillance, as an alternative to PCI. The 
salvage whole-brain RT for treatment of brain metastases does not 
appear to have a detrimental effect on OS [129-131]. More studies 
are needed to confirm these data.
3. Discussion
The National Comprehensive Cancer Network (NCCN), 
ASTRO, ASCO, and ESMO guidelines recommend surgery as 
the initial treatment option in operable patients having a well-
staged cT1-2N0M0 (I-IIA) of the American Joint Committee on 
Cancer and the International Union for Cancer Control update 
tumor-node-metastasis (TNM) cancer staging system. Pathologic 
mediastinal staging would be mandatory before surgical 
indication to identifying patients with a very limited disease. 
These recommendations are based on many small series, largely 
retrospective, Phase II trials, meta-analysis, systematic reviews, 
and propensity matched score analysis that has shown excellent 
survival for patients with T1-2N0SCLC who underwent surgical 
treatment, mainly in the setting of a multimodal approach [132]. 
Lobectomy with systematic lymph node dissection is the 
recommended type of resection.
Notwithstanding, there is a clear underuse of surgery in the 
treatment of ES-SCLC. Wakeam et al. identified 9740 patients with 
cT1 or cT2N0M0 SCLC cases from the National Cancer Database 
(2004-2013), of which only 2210 (22.7%) underwent surgery in 
spite of having no recognizable contraindication. Remarkably, 
between 2004 and 2013, the resection rates raised from 9.1% to 
21.7%. The authors suggest studies addressed to found the reason 
for this mismatch between guidelines and practice [133]. The same 
group also showed that there is a large variability in the surgical 
indication and type of resection for ES-SCLC, but also in survival 
and mortality in the current clinical practice in the United States, 
which may represent a substantial opportunity for improvement in 
patients with ES-SCLC [134].
Almost 10 years have passed since Shepherd published in 
the Journal of Thoracic Oncology the editorial entitled “Surgery 
for Limited Stage Small Cell Lung Cancer. Time to Fish or Cut 
Bait” urging the international community to join forces to plan a 
prospective trial to answer the question of the role of surgery in 
the treatment of ES-SCLC [135].
While surgery is considered the preferred local therapy in T1-
2N0 SCLC, increasing data support the role of SBRT for inoperable 
Stage I SCLC, transferring the favorable experience obtained on 
inoperable early NSCLC. SBRT shows comparable local control 
outcomes to surgical and CRT series, even though there are no 
randomized studies comparing both treatments. Use of SBRT in 
early-SCLC as in NSCLC seems safe and does not increase the 
risk of toxicity. The pattern of failure in SBRT series is regional in 
25% of cases and distant in 50%. To correctly assess the impact of 
SBRT on the survival of stage I SCLC is highly recommendable 
to systematically perform a correct regional and distant staging: 
18-FDG PET-CT scan, mediastinoscopy, and/or EBUS.
SCLC is a tumor with a high trend to early spreading and it 
is unknown why a high percentage of patients did not receive 
chemotherapy. The data from surgical, CRT, and SBRT series 
support multimodal treatment with neoadjuvant or adjuvant 
chemotherapy and PCI even in early-SCLC. Systemic treatment 
showed significant increase in OS in both surgical and SBRT 
series. According to the analyzed data, the range of benefit in OS 
at 5 years goes from 10% to 30%, with a significant advantage 
in the chemotherapy group. The sequence of systemic treatment 
– neoadjuvant/adjuvant – showed no significant impact in OS. 
However, in the context of a local primary treatment, surgery or 
SBRT, it seems more reasonable that it be adjuvant.
PCI is associated with a significant reduction of brain 
metastases in SCLC. The selected group of early SCLC has a 
lower risk of brain metastasis; which is estimated between 10 
and 15%. The impact on survival is lower than in other stages. 
The most appropriate approach is unclear. Active brain MRI 
surveillance may be an alternative option to PCI, especially in 
very early stage (T1N0M0) SCLC. More studies are needed to 
confirm these data.
According to the current data, it is difficult to compare 
surgery and SBRT treatments. The patients in each group of 
treatment have different characteristics in terms of age and 
comorbidities. Surgery started earlier than SBRT as a local 
treatment of early SCLC. Surgical series are extensive, with 
many patients analyzed, long-term follow-up, and robust 
conclusions; on the other hands, SBRT is a new emergent 
treatment for early stage SCLC; therefore, current available 
studies are retrospective, heterogeneous, and with a small 
number of patients. Despite this, preliminary results of SBRT 
are promising and warrant future research. The advantage of 
SBRT over surgery is that it can be performed in elderly patients 
with altered respiratory function or other comorbidities, without 
increasing toxicity. Local control is similar for both treatments, 
although regional relapse was superior in SBRT series, probably 
due to a mediastinal understaging in SBRT series. Therefore, it 
is difficult to compare both treatments and should be further 
investigated in randomized clinical trials.
Taking into account the data analyzed, the limitations of the 
series reviewed, and the recommendations of the international 
guidelines, we propose our approach in the management of 
T1-2N0 SCLC considering: Staging, operability, criteria for 
SBRT, ability to systemic therapy and benefit of PCI (Figure 2).
4. Conclusion
T1-2N0M0SCLC represents a highly selected group of 
patients who, despite having a very localized disease, requires a 
multimodal approach due to the aggressive nature of the disease. 
In spite of the absence of randomized studies, the current data 
and guidelines recommend surgical treatment of well-staged early 
SCLC (cT1-2N0M0) in patients fit enough for surgery. Lobectomy 
plus systematic nodal dissection is the preferred type of resection. 
Nowadays, RT is the therapeutic option in those with surgical 
contraindication, despite the lack of high quality clinical evidence; 
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SBRT is an emerging technique that is safe and effective for 
inoperable early stage SCLC. All patients should receive systemic 
therapy due to the tendency of SCLC to metastasize early, with 
the aim of increasing OS. PCI must be evaluated individually by 
a multidisciplinary team.
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